|
Market Cap | 76.61M | EPS (ttm) | 0.17 |
P/E | 126.37 | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | -30.30% |
P/S | 2.27 | EPS next 5Y | - |
P/B | 1.02 | EPS Q/Q | -9.89% |
Dividend | 4.92% | Sales Q/Q | 14.11% |
Insider Own | 56.60% | Inst Own | 7.56% |
Insider Trans | 0.68% | Inst Trans | -8.35% |
Short Float | 0.53% | Earnings | Jul 23/b |
Analyst Recom | - | Target Price | - |
Avg Volume | 5.71K | 52W Range | 16.48 - 25.25 |
|
|
|
Auburn National Bancorporation, Inc. is a bank holding company. It engages in the provision of banking services to commercial and retail customers. The firm operates through the following segments: Commercial and Industrial, Construction and Land Development, Commercial Real Estate, Residential Real Estate, and Consumer Installment. The Commercial and Industrial segment includes loans to finance business operations, equipment purchases, or other needs for small and medium-sized commercial customers. The Construction and Land Development segment is comprised of both loans and credit lines for the purpose of purchasing, carrying and developing land into commercial developments or residential subdivisions. The Commercial and Industrial segment provides loans disaggregated into three classes: owner occupied, multi-family and other. The Residential Real Estate segment is involved in consumer mortgage and investment property. The Consumer Installment segment encompasses loans to individuals both secured by personal property and unsecured. The company was founded in 1990 and is headquartered in Auburn, AL. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
HAM WILLIAM F JR | Director | Oct 01 '24 | Buy | 23.38 | 61 | 1,426 | 4,679 | Oct 01 02:18 PM | O'DONNELL SHANNON | Senior Vice President | Oct 01 '24 | Buy | 23.34 | 29 | 677 | 1,422 | Oct 01 02:13 PM | HOUSEL DAVID E | Director | Oct 01 '24 | Buy | 23.36 | 55 | 1,285 | 7,771 | Oct 01 02:06 PM | Barrett J Tutt | Director | Oct 01 '24 | Buy | 23.36 | 78 | 1,822 | 8,732 | Oct 01 01:55 PM | HOUSEL DAVID E | Director | Aug 30 '24 | Buy | 19.17 | 100 | 1,917 | 7,716 | Sep 03 04:09 PM |
|
|
|
|
Market Cap | 81.90M | EPS (ttm) | -0.11 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | -11.82% |
P/S | 0.35 | EPS next 5Y | - |
P/B | 0.65 | EPS Q/Q | -358.62% |
Dividend | - | Sales Q/Q | -9.09% |
Insider Own | 81.66% | Inst Own | 4.64% |
Insider Trans | 0.03% | Inst Trans | -0.93% |
Short Float | 0.31% | Earnings | - |
Analyst Recom | - | Target Price | - |
Avg Volume | 15.92K | 52W Range | 7.77 - 14.69 |
|
|
|
Bridgford Foods Corp. engages in the manufacture, market, and distribution of frozen and snack food products. It operates through the Frozen Food Products and Snack Food Products segments. The Frozen Food Products segment manufactures and distributes food products, including biscuits, bread dough items, roll dough items, and sandwiches. The Snack Food Products segment distributes both products manufactured by the company and third parties. The company was founded by Hugh H. Bridgford in February 1932 and is headquartered in Dallas, TX. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Bridgford Brian E. | V.P. Production | Oct 01 '24 | Buy | 9.10 | 300 | 2,730 | 3,011 | Oct 01 02:11 PM | Bridgford Brian E. | V.P. Production | Sep 11 '24 | Buy | 8.71 | 500 | 4,355 | 2,711 | Sep 13 04:48 PM | Bridgford Allan Jr. | Consultant | Sep 11 '24 | Buy | 8.80 | 1,000 | 8,800 | 44,000 | Sep 13 02:29 PM | Bridgford Richard Eugene | V.P. Ind. Relations & Safety | Sep 11 '24 | Buy | 8.60 | 105 | 903 | 2,700 | Sep 11 05:06 PM | Bridgford Richard Eugene | V.P. Ind. Relations & Safety | Sep 09 '24 | Buy | 8.60 | 200 | 1,720 | 2,595 | Sep 10 12:43 PM |
|
|
|
|
Market Cap | 295.83M | EPS (ttm) | -5.36 |
P/E | - | EPS this Y | 98.95% |
Forward P/E | - | EPS next Y | -11.95% |
PEG | - | EPS past 5Y | - |
P/S | - | EPS next 5Y | - |
P/B | 1.28 | EPS Q/Q | -544.47% |
Dividend | - | Sales Q/Q | - |
Insider Own | 63.38% | Inst Own | 35.78% |
Insider Trans | -0.15% | Inst Trans | 11.13% |
Short Float | 1.34% | Earnings | Sep 10/a |
Analyst Recom | 1.00 | Target Price | 30.17 |
Avg Volume | 193.76K | 52W Range | 4.42 - 47.17 |
|
|
|
enGene Holdings, Inc. is a clinical-stage biotechnology company, which engages in developing gene therapies. It is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs. The company was founded by Anthony T. Cheung on April 24, 2023 and is headquartered in Saint-Laurent, Canada. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Cooper Ronald Harold Wilfred | Chief Executive Officer | Sep 27 '24 | Buy | 5.70 | 10,000 | 57,000 | 10,000 | Oct 01 08:02 AM | Glickman Richard M | Director | May 28 '24 | Option Exercise | 0.89 | 120 | 107 | 24,675 | May 29 06:12 PM | FONDS DE SOLIDARITE DES TRAVAI | 10% Owner | Apr 22 '24 | Sale | 15.00 | 47,854 | 717,810 | 3,036,153 | Apr 22 05:22 PM | FONDS DE SOLIDARITE DES TRAVAI | 10% Owner | Apr 18 '24 | Sale | 15.01 | 4,575 | 68,671 | 3,084,107 | Apr 22 05:22 PM | FONDS DE SOLIDARITE DES TRAVAI | 10% Owner | Apr 19 '24 | Sale | 15.00 | 100 | 1,500 | 3,084,007 | Apr 22 05:22 PM |
|
|
| |
|
Market Cap | 1.78B | EPS (ttm) | -4.25 |
P/E | - | EPS this Y | 27.08% |
Forward P/E | - | EPS next Y | -8.00% |
PEG | - | EPS past 5Y | 20.35% |
P/S | 6124.60 | EPS next 5Y | - |
P/B | 4.51 | EPS Q/Q | 20.05% |
Dividend | - | Sales Q/Q | 0.00% |
Insider Own | 13.08% | Inst Own | 82.42% |
Insider Trans | 19.45% | Inst Trans | 0.31% |
Short Float | 15.76% | Earnings | Aug 08/b |
Analyst Recom | 1.12 | Target Price | 39.56 |
Avg Volume | 1.49M | 52W Range | 10.93 - 24.75 |
|
|
|
Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Beetham Thomas W. | Chief Operating Officer | Sep 27 '24 | Buy | 23.41 | 5,000 | 117,050 | 6,000 | Sep 30 07:12 PM | Mahoney Stephen F. | President and CEO | Sep 27 '24 | Buy | 23.33 | 21,400 | 499,262 | 21,400 | Sep 30 07:10 PM | Fairmount Funds Management LLC | Director | Sep 13 '24 | Buy | 18.75 | 1,600,000 | 30,000,000 | 3,445,813 | Sep 17 09:00 PM | Fairmount Funds Management LLC | Director | Jan 22 '24 | Buy | 21.00 | 476,190 | 9,999,990 | 1,839,954 | Jan 24 06:44 PM |
|
|
|
|
Market Cap | 198.25M | EPS (ttm) | -2.33 |
P/E | - | EPS this Y | 79.81% |
Forward P/E | - | EPS next Y | 44.41% |
PEG | - | EPS past 5Y | -19.80% |
P/S | 1.26 | EPS next 5Y | - |
P/B | 0.71 | EPS Q/Q | 70.37% |
Dividend | - | Sales Q/Q | 1.28% |
Insider Own | 5.88% | Inst Own | 35.93% |
Insider Trans | -0.14% | Inst Trans | 28.26% |
Short Float | 26.59% | Earnings | Aug 07/a |
Analyst Recom | 1.75 | Target Price | 4.25 |
Avg Volume | 4.70M | 52W Range | 1.53 - 4.66 |
|
|
|
Blink Charging Co. engages in the operation and provision of electric vehicles, charging equipment, and networked EV charging services. Its product line and services include the Blink EV charging network, charging equipment, also known as electric vehicle supply equipment, and EV charging services. The company was founded by Michael D. Farkas on October 3, 2006 and is headquartered in Bowie, MD. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
LEVINE JACK | Director | Sep 26 '24 | Buy | 1.70 | 20,000 | 34,000 | 175,718 | Sep 30 06:00 PM | Peterson Kristina A. | Director | Sep 19 '24 | Sale | 1.80 | 24,077 | 43,377 | 0 | Sep 23 06:00 PM | Peterson Kristina A. | Director | Jun 25 '24 | Sale | 2.77 | 4,510 | 12,515 | 0 | Jun 27 05:00 PM |
|
|
| |
|
Market Cap | 170.80M | EPS (ttm) | -0.63 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | -12.15% |
P/S | 3.95 | EPS next 5Y | - |
P/B | 2.74 | EPS Q/Q | -31.96% |
Dividend | - | Sales Q/Q | 30.92% |
Insider Own | 24.80% | Inst Own | 40.01% |
Insider Trans | 0.52% | Inst Trans | 1.13% |
Short Float | 5.62% | Earnings | - |
Analyst Recom | - | Target Price | - |
Avg Volume | 45.99K | 52W Range | 4.06 - 10.99 |
|
|
|
Empire Petroleum Corp. engages in the exploration and development of oil and natural gas. The company possesses long-life, low operational cost, mature, producing assets with slow decline profiles in the Permian Basin, Bakken region and central Gulf Coast region, in the states of New Mexico, North Dakota, Montana, Louisiana, and Texas. Empire focuses on economical well rehabilitation, stimulation, field maintenance and management to generate low-risk cash flows that provides stability and growth for shareholders. The company was founded in August 1983 and is headquartered in Tulsa, OK. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Mulacek Phil E | Director | Sep 25 '24 | Buy | 4.98 | 1,373 | 6,838 | 4,706,493 | Sep 30 05:54 PM | Mulacek Phil E | Director | Sep 30 '24 | Buy | 5.16 | 741 | 3,824 | 4,707,234 | Sep 30 05:54 PM | Mulacek Phil E | Director | Jun 25 '24 | Buy | 5.29 | 33,295 | 176,131 | 4,700,472 | Jul 01 07:12 AM | Mulacek Phil E | Director | Jun 28 '24 | Buy | 5.39 | 4,648 | 25,053 | 4,705,120 | Jul 01 07:12 AM | Mulacek Phil E | Director | Jun 28 '24 | Buy | 5.62 | 600 | 3,372 | 534,936 | Jul 01 07:12 AM |
|
|
|
|
Market Cap | 1.60B | EPS (ttm) | - |
P/E | - | EPS this Y | -10.79% |
Forward P/E | - | EPS next Y | 27.03% |
PEG | - | EPS past 5Y | - |
P/S | - | EPS next 5Y | - |
P/B | 4.12 | EPS Q/Q | -627.95% |
Dividend | - | Sales Q/Q | - |
Insider Own | 51.64% | Inst Own | 37.66% |
Insider Trans | -0.07% | Inst Trans | -16.08% |
Short Float | 0.97% | Earnings | Aug 07/b |
Analyst Recom | 1.20 | Target Price | 37.00 |
Avg Volume | 361.26K | 52W Range | 5.63 - 26.35 |
|
|
|
NewAmsterdam Pharma Co. NV is a clinical-stage biopharmaceutical company, which engages in the development of oral, non-statin medicine for patients at high risk of cardiovascular disease with residual elevation of low-density lipoprotein cholesterol. Its lead product candidate, Obicetrapib, is a next-generation, oral, low-dose cholesteryl ester transfer protein inhibitor, which will be used to prevent major adverse cardiovascular events. The company was founded on June 10, 2022 and is headquartered in Naarden, the Netherlands. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Kooij Louise Frederika | Chief Accounting Officer | Oct 01 '24 | Sale | 15.72 | 45,000 | 707,400 | 0 | Oct 01 05:23 PM | Kooij Louise Frederika | Officer | Oct 01 '24 | Proposed Sale | 17.29 | 45,000 | 778,050 | | Oct 01 05:12 PM | Audet Juliette Berangere | Chief Business Officer | Sep 26 '24 | Buy | 15.70 | 1,104 | 17,333 | 1,104 | Sep 30 05:22 PM | Davidson Michael H. | Chief Executive Officer | Aug 20 '24 | Buy | 16.27 | 5,000 | 81,350 | 209,784 | Aug 22 04:30 PM | Davidson Michael H. | Chief Executive Officer | Jun 20 '24 | Buy | 17.26 | 5,000 | 86,308 | 204,784 | Jun 24 08:30 AM |
|
|
| |
|
Market Cap | 120.90M | EPS (ttm) | -10.75 |
P/E | - | EPS this Y | 3.42% |
Forward P/E | - | EPS next Y | 50.97% |
PEG | - | EPS past 5Y | 52.49% |
P/S | - | EPS next 5Y | - |
P/B | - | EPS Q/Q | 45.02% |
Dividend | - | Sales Q/Q | - |
Insider Own | 35.60% | Inst Own | 35.99% |
Insider Trans | 0.06% | Inst Trans | 15.95% |
Short Float | 16.21% | Earnings | Aug 14/b |
Analyst Recom | 1.14 | Target Price | 37.43 |
Avg Volume | 224.73K | 52W Range | 4.40 - 18.00 |
|
|
|
Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. The company was founded by Pankaj Mohan on January 5, 2010 and is headquartered in Iselin, NJ. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
KENYON LAWRENCE A | Chief Financial Officer | Sep 26 '24 | Buy | 5.69 | 5,000 | 28,446 | 5,946 | Sep 30 04:53 PM | Haddadin Yezan Munther | Director | Mar 28 '24 | Buy | 11.82 | 1,882 | 22,242 | 5,049 | Mar 29 10:39 AM | Evanson Jeff | CHIEF COMMERCIAL OFFICER | Mar 07 '24 | Buy | 0.42 | 62,484 | 26,243 | 808,459 | Mar 11 04:43 PM |
|
|
|
|
Market Cap | 108.71M | EPS (ttm) | -0.20 |
P/E | - | EPS this Y | -150.00% |
Forward P/E | - | EPS next Y | -20.00% |
PEG | - | EPS past 5Y | -6.25% |
P/S | 0.54 | EPS next 5Y | 15.00% |
P/B | 1.14 | EPS Q/Q | 18.99% |
Dividend | - | Sales Q/Q | -3.41% |
Insider Own | 8.18% | Inst Own | 73.15% |
Insider Trans | 6.09% | Inst Trans | -10.72% |
Short Float | 0.19% | Earnings | Aug 07/a |
Analyst Recom | 2.00 | Target Price | 3.88 |
Avg Volume | 184.27K | 52W Range | 1.55 - 3.18 |
|
|
|
Brightcove, Inc. engages in the provision of video cloud solutions. The firm enables its customers to publish and distribute video to Internet-connected devices. Its products include Brightcove Video Cloud, Brightcove Live, Brightcove Beacon, Brightcove Player, Zencoder, and Brightcove Audience Insights. The company was founded by Jeremy J. Allaire and Robert Mason in August 2004 and is headquartered in Boston, MA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Edenbrook Capital, LLC | 10% Owner | Sep 26 '24 | Buy | 2.07 | 20,000 | 41,400 | 6,651,535 | Sep 30 04:50 PM | Edenbrook Capital, LLC | 10% Owner | Sep 19 '24 | Buy | 2.00 | 2,901 | 5,802 | 6,631,535 | Sep 19 05:08 PM | Edenbrook Capital, LLC | 10% Owner | Sep 18 '24 | Buy | 2.00 | 2,096 | 4,192 | 6,628,634 | Sep 19 05:08 PM | Edenbrook Capital, LLC | 10% Owner | Sep 12 '24 | Buy | 2.00 | 5,003 | 10,006 | 6,626,538 | Sep 16 04:29 PM | Edenbrook Capital, LLC | 10% Owner | Sep 06 '24 | Buy | 2.04 | 11,600 | 23,674 | 6,616,305 | Sep 10 04:22 PM |
|
|
|
|
Market Cap | 543.84M | EPS (ttm) | 1.96 |
P/E | 13.76 | EPS this Y | 81.77% |
Forward P/E | 9.22 | EPS next Y | 21.28% |
PEG | 1.72 | EPS past 5Y | -11.76% |
P/S | 1.72 | EPS next 5Y | 8.00% |
P/B | 0.78 | EPS Q/Q | 107.11% |
Dividend | 3.59% | Sales Q/Q | 34.40% |
Insider Own | 9.52% | Inst Own | 54.22% |
Insider Trans | 0.80% | Inst Trans | 0.61% |
Short Float | 0.26% | Earnings | Jul 25/a |
Analyst Recom | 2.20 | Target Price | 31.10 |
Avg Volume | 55.68K | 52W Range | 19.19 - 30.51 |
|
|
|
MidWestOne Financial Group, Inc. is a financial holding company, focuses on delivering relationship-based business and personal banking products and services through its bank subsidiary, MidWestOne Bank. The Bank provides commercial loans, real estate loans, agricultural loans, credit card loans, and consumer loans. It also provides deposit products including demand and interest checking accounts, savings accounts, money market accounts, and time deposits. The Bank also provides products and services including treasury management, Zelle, online and mobile banking, debit cards, ATMs, and safe deposit boxes. It offers its products and services primarily through its full-service branch network, including 34 branches located throughout central and eastern Iowa, 13 branches located principally in the Minneapolis-St. Paul metropolitan area of Minnesota, seven branches in western Wisconsin, one branch in each of Naples and Fort Myers, Florida, and one branch in Denver, Colorado. MidWestOne Financial Group was founded in 1983 and is headquartered in Iowa City, IA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Hayek Matthew J | Director | Sep 30 '24 | Buy | 25.00 | 2,000 | 50,000 | 11,293 | Sep 30 04:40 PM | GREEFF DOUGLAS H | Director | Sep 30 '24 | Buy | 25.00 | 4,000 | 100,000 | 13,891 | Sep 30 04:40 PM | Sims Gary L | SVP & Chief Credit Officer | Sep 30 '24 | Buy | 25.00 | 2,000 | 50,000 | 15,378 | Sep 30 04:40 PM | McCormick Tracy S | Director | Sep 30 '24 | Buy | 25.00 | 2,000 | 50,000 | 92,565 | Sep 30 04:39 PM | ALBERT LARRY D | Director | Sep 30 '24 | Buy | 25.00 | 600 | 15,000 | 17,503 | Sep 30 04:39 PM |
|
|
|